Liu Qian, Jin Pengfei, Li Jingxin, Chen Xiaoqin, Wang Chenhao, Lu Qingbin, Jiang Wei, Zhang Shixuan, Jin Lairun, Pan Hongxin, Guo Xue, Zhu Fengcai
School of Public Health, Southeast University, Nanjing City, Jiangsu Province, China.
Jiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing City, Jiangsu Province, China.
China CDC Wkly. 2024 May 10;6(19):424-430. doi: 10.46234/ccdcw2024.082.
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: The quadrivalent influenza vaccine (QIV) provides protection against a broader range of influenza strains by including strains of influenza A/H1N1, A/H3N2, B/Yamagata, and B/Victoria.
WHAT IS ADDED BY THIS REPORT?: This study aimed to assess the immunogenicity and safety of administering a single dose compared to two doses of QIV in children, taking into consideration their previous influenza vaccination history.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: This study provides evidence supporting the use of a single dose of the QIV in children aged 3-8 years who have previously received two or more doses of influenza vaccine. However, children who have not been previously vaccinated with influenza vaccine should still adhere to the recommended schedule of receiving two doses.
关于该主题已知的信息有哪些？：四价流感疫苗（QIV）通过包含甲型H1N1、甲型H3N2、乙型山形和乙型维多利亚流感毒株，可提供针对更广泛流感毒株的保护。
本报告新增了哪些内容？：本研究旨在评估在考虑儿童既往流感疫苗接种史的情况下，与两剂QIV相比，单剂QIV的免疫原性和安全性。
对公共卫生实践有何启示？：本研究提供了证据，支持在既往已接种两剂或更多剂流感疫苗的3至8岁儿童中使用单剂QIV。然而，既往未接种过流感疫苗的儿童仍应遵循推荐的两剂接种程序。
